CoChat

Two double-blind placebo-controlled pilot studies of eicosapentaenoic acid in the treatment of schizophrenia

Peet, Malcolm, Brind, Jan, Ramchand, C.N., Shah, Sandeep, Vankar, G.K. · 2001 · Schizophrenia Research

The DOI matches its Crossref record; 65 of the 67 references it cites were found in a registry or an index.

Abstract

Evidence that the metabolism of phospholipids and polyunsaturated fatty acids (PUFA) is abnormal in schizophrenia provided the rationale for intervention studies using PUFA supplementation. An initial open label study indicating efficacy for n-3 PUFA in schizophrenia led to two small double-blind pilot studies. The first study was designed to distinguish between the possible effects of two different n-3 PUFA: eicosapentaenoic acid (EPA) and docohexaenoic acid (DHA). Forty-five schizophrenic patients on stable antipsychotic medication who were still symptomatic were treated with either EPA, DHA or placebo for 3 months. Improvement on EPA measured by the Positive and Negative Syndrome Scale (PANSS) was statistically superior to both DHA and placebo using changes in percentage scores on the total PANSS. EPA was significantly superior to DHA for positive symptoms using ANOVA for repeated measures. In the second placebo-controlled study, EPA was used as a sole treatment, though the use of antipsychotic drugs was still permitted if this was clinically imperative. By the end of the study, all 12 patients on placebo, but only eight out of 14 patients on EPA, were taking antipsychotic drugs. Despite this, patients taking EPA had significantly lower scores on the PANSS rating scale by the end of the study. It is concluded that EPA may represent a new treatment approach to schizophrenia, and this requires investigation by large-scale placebo-controlled trials.

Overview

Integrity signals

Registry

Crossref · 10.1016/s0920-9964(00)00083-9

Cites

65 of 65 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 65 references

Research works printed but not linked: 2

  1. Mellor, 1996, Omega-3 fatty acid supplementation in schizophrenic patients, Human Psychopharmacol., 11, 39, 10.1002/(sici)1099-1077(199601)11:1<39::aid-hup742>3.0.co;2-# · doi:10.1002/(sici)1099-1077(199601)11:1<39::aid-hup742>3.0.co;2-#
  2. Shah, 2000, Lack of niacin skin flush response in unmedicated schizophrenic patients, Schizophr. Res

Cited by

See all 333

Metadata

Authors
Peet, M., Brind, J., Ramchand, C. N., Shah, S., & Vankar, G. K.
Affiliations
  • Northern General Hospital (GB)
  • Sir Sayajirao General Hospital Medical College (IN)
Corresponding author
Peet, Malcolm
Venue
Schizophrenia Research
Publisher
Elsevier BV
Published
2001-04
Volume
49
Issue
3
Pages
243-251
ISSN
0920-9964 (ISSN-L)
OpenAlex
W1975464025
Cited by
329
References
67
Citations by year
2026: 4 · 2025: 2 · 2024: 5 · 2023: 2 · 2022: 6 · 2021: 12 · 2020: 11 · 2019: 10 · 2018: 6 · 2017: 14 · 2016: 11 · 2015: 19 · 2014: 15 · 2013: 14 · 2012: 14
FWCI
19.77
Type
journal article
Language
en
Open access
closed
Licence
www.elsevier.com/tdm/userlicense/1.0/ (tdm)
Locations
  • Schizophrenia Research (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Nursing › Nutrition and Dietetics › Fatty Acid Research and Health
  • Health Sciences › Medicine › Psychiatry and Mental health › Schizophrenia research and treatment
  • Life Sciences › Neuroscience › Biological Psychiatry › Tryptophan and brain disorders
Keywords
eicosapentaenoic acid, docosahexaenoic acid
MeSH terms
Adult, Arachidonic Acids, Docosahexaenoic Acids, Double-Blind Method, Humans, Pilot Projects, Schizophrenia, Schizophrenic Psychology, Antipsychotic Agents

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Two double-blind placebo-controlled pilot studies of eicosapentaenoic acid in the treatment of schizophrenia. https://app.cochat.ai/papers/10.1016/s0920-9964(00)00083-9
The paper
Peet, M., Brind, J., Ramchand, C. N., Shah, S., & Vankar, G. K. (2001). Two double-blind placebo-controlled pilot studies of eicosapentaenoic acid in the treatment of schizophrenia. Schizophrenia Research. https://doi.org/10.1016/s0920-9964(00)00083-9

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.